ASCO 2022 Conference Coverage
Lecture Summary - ASCO 2022 Nivolumab + Relatlimab vs. Nivo in 1L Metastatic/Unresectable Melanoma: OS & ORR by Key Subgroups From the RELATIVITY-047
By
ASCO 2022 Conference Coverage
FEATURING
Piotr Rutkowski
By
ASCO 2022 Conference Coverage
FEATURING
Piotr Rutkowski
Login to view comments.
Click here to Login
